Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Teneobio, Inc.
Deal Watch: Merck Looks To Technology Platform Partners For Cytokine Agonist Discovery, Drug Delivery
Plus deals involving Moderna/Metagenomi, Agomab/Origo, Selecta/Ginkgo, Teva/MODAG, Boehringer Ingelheim/Thoeris and X-Chem/ComInnex/Glamorous AI.
Takeda will use Poseida’s non-viral delivery and gene-editing capabilities for six liver- and hematopoietic stem cell-targeted gene therapies. The agreement follows recent gene therapy tie-ups with Selecta and Genevant.
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.
- Drug Discovery Tools
- Other Names / Subsidiaries
- OMT Therapeutics Inc
- Recombinant Antibody Technology (RAT) Ltd.